Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Decroo

Showing results (91-100 of 138) with videos related to

Pageof 14
Sort By:
International Journal of Antimicrobial Agents|October 19, 2019
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forwardArmand Van Deun, Tom Decroo, Sabira Tahseen, et al.
Plos One|January 29, 2024
Correction: Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, IndiaChinmay Laxmeshwar, Mrinalini Das, Taanya Mathur, et al.
Plos One|February 11, 2022
Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, IndiaChinmay Laxmeshwar, Mrinalini Das, Taanya Mathur, et al.
Plos One|December 22, 2023
Implementation of the advanced HIV disease care package with point-of-care CD4 testing during tuberculosis case finding: A mixed-methods evaluationTinne Gils, Mashaete Kamele, Thandanani Madonsela, et al.
Plos One|October 19, 2020
Patient-mix, programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV "Treat All" in ZimbabweRichard Makurumidze, Jozefien Buyze, Tom Decroo, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 7, 2023
High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicinMahamadou Bassirou Souleymane, Sani Kadri, Alberto Piubello, et al.
Trials|December 13, 2022
Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisationMahamadou Bassirou Souleymane, Tom Decroo, Alphazazi Soumana, et al.
Plos One|January 8, 2020
Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe's national antiretroviral therapy programme between 2012 and 2015Richard Makurumidze, Tsitsi Mutasa-Apollo, Tom Decroo, et al.
AIDS Research and Therapy|July 9, 2022
Virological outcomes and risk factors for non-suppression for routine and repeat viral load testing after enhanced adherence counselling during viral load testing scale-up in Zimbabwe: analytic cross-sectional study using laboratory data from 2014 to 2018Trudy Tholakele Mhlanga, Bart K M Jacobs, Tom Decroo, et al.
Plos One|May 19, 2020
The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistanceArmand Van Deun, Tom Decroo, Aung Kya Jai Maug, et al.
Pageof 14

Showing results (91-100 of 138) with videos related to

Sort By:
Pageof 14
International Journal of Antimicrobial Agents|October 19, 2019
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forwardArmand Van Deun, Tom Decroo, Sabira Tahseen, et al.
Plos One|January 29, 2024
Correction: Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, IndiaChinmay Laxmeshwar, Mrinalini Das, Taanya Mathur, et al.
Plos One|February 11, 2022
Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, IndiaChinmay Laxmeshwar, Mrinalini Das, Taanya Mathur, et al.
Plos One|December 22, 2023
Implementation of the advanced HIV disease care package with point-of-care CD4 testing during tuberculosis case finding: A mixed-methods evaluationTinne Gils, Mashaete Kamele, Thandanani Madonsela, et al.
Plos One|October 19, 2020
Patient-mix, programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV "Treat All" in ZimbabweRichard Makurumidze, Jozefien Buyze, Tom Decroo, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 7, 2023
High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicinMahamadou Bassirou Souleymane, Sani Kadri, Alberto Piubello, et al.
Trials|December 13, 2022
Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisationMahamadou Bassirou Souleymane, Tom Decroo, Alphazazi Soumana, et al.
Plos One|January 8, 2020
Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe's national antiretroviral therapy programme between 2012 and 2015Richard Makurumidze, Tsitsi Mutasa-Apollo, Tom Decroo, et al.
AIDS Research and Therapy|July 9, 2022
Virological outcomes and risk factors for non-suppression for routine and repeat viral load testing after enhanced adherence counselling during viral load testing scale-up in Zimbabwe: analytic cross-sectional study using laboratory data from 2014 to 2018Trudy Tholakele Mhlanga, Bart K M Jacobs, Tom Decroo, et al.
Plos One|May 19, 2020
The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistanceArmand Van Deun, Tom Decroo, Aung Kya Jai Maug, et al.
Pageof 14